Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) probably leads to lower burning sensation (VAS 0-100) compared with placebo or no active treatment (moderate certainty).
3 findings from 1 review
MD -70.82 [-94.39, -47.25]
2 studies · 500 participants
Moderate
MD -30.92 [-31.57, -30.27]
1 study · 400 participants
Moderate
MD -27.60 [-36.21, -18.99]
1 study · 90 participants
Moderate
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) showed no clear difference in maximal mouth opening (interincisal distance) compared with placebo or no active treatment (low certainty).
3 findings from 1 review
MD -1.41 [-5.74, 2.92]
1 study · 90 participants
Low
MD 3.11 [0.46, 5.77]
2 studies · 520 participants
Low
MD 8.83 [8.22, 9.45]
3 studies · 620 participants
Moderate
Difficulty in speech (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline led to lower difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Discomfort/pain · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Difficulty in swallowing (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline led to lower difficulty in swallowing (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Change in probing pocket depth (PPD) · Adults (> 18 years) with peri-implant mucositis, receiving active treatment
Adjunctive antimicrobial photodynamic therapy (aPDT) applied after… showed no clear difference in change in probing depth (PD/PPD) compared with submucosal instrumentation (SI) alone, or SI plus placebo/sham aPDT; GRADE not reported.
1 finding from 1 review
Difficulty in speech (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) showed no clear difference in difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Patient satisfaction · Adults (> 18 years) with peri-implant mucositis, receiving active treatment
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · Adults (> 18 years) with a clinical diagnosis of periodontitis, receiving active (non-surgical anti-infective) treatment
The review found no eligible studies for this question.
1 finding from 1 review
Any adverse effect related to aPDT · Adults (> 18 years) with peri-implant mucositis, receiving active treatment
The review found no eligible studies for this question.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Cardiovascular events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found